TICKERNERD
Menu
TYRATYRAHealthcare · Biotechnology

TYRA Stock Forecast: Tyra Biosciences, Inc. Price Predictions for 2026-2027

Last close, 4 Sept 2026
$29
+15.25% on the day

The 15 Wall Street analysts covering Tyra Biosciences, Inc. hold a median 12-month price target of $53 — +85.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 7 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.7B
Ticker Nerd rank
32 / 100
Median analyst target
$53
Analysts covering
15
Revenue$0.0
Operating income−$49.0M
Net income−$45.6M
Free cash flow−$31.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+14.9%
1M
−11.9%
YTD
+9.0%
1Y
+136.0%
From 52W high
−27.7%
From 52W low
+142.4%
$12
$40
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TYRA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tyra Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Sept 2026
32 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
81
Volatility
72
Value
53
Accruals
44
Issuance
42
Size
38
Quality
34
Revisions
30
Growth
27

Momentum (81): The shares have been drifting up relative to others.

Growth (27): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TYRA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TYRA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26TYRAHigh $59Median $53Low $39

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
14 Buy1 Hold0 Sell
Low $39Median $53High $59

The green dot is the last close — the median target sits +85.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
4 Sept 2026HC Wainwright & Co.ReiteratesBuy$45
17 June 2026Jones TradingInitiatesBuy$56
17 June 2026Jones TradingInitiatesBuy—
10 June 2026B of A SecuritiesMaintainsBuy$37 → $42
10 June 2026B of A SecuritiesMaintainsBuy—
19 May 2026Wolfe ResearchInitiatesPeer Perform—
14 May 2026HC Wainwright & Co.ReiteratesBuy—
15 Apr 2026GuggenheimInitiatesBuy—
6 Apr 2026Canaccord GenuityInitiatesBuy—
20 Mar 2026Piper SandlerMaintainsOverweight—
24 Feb 2026Cantor FitzgeraldInitiatesOverweight—
17 Feb 2026HC Wainwright & Co.MaintainsBuy—
13 Feb 2026WedbushMaintainsOutperform—
3 Feb 2026JefferiesMaintainsBuy—
3 Feb 2026OppenheimerMaintainsOutperform—
28 Jan 2026BarclaysInitiatesOverweight—
23 Jan 2026Piper SandlerMaintainsOverweight—
16 Dec 2025WedbushMaintainsOutperform—
3 Sept 2025Raymond JamesInitiatesStrong Buy—
22 Aug 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TYRA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TYRA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Sept 2026, Tyra Biosciences, Inc. returned +136.0% against +20.0% for the S&P 500, dividends included.

TYRA vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Oct 25Jan 26Apr 26Jul 26TYRAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TYRA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
11
Fundamentals

Tyra Biosciences, Inc. (TYRA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−14.2×

Cheaper than 94% of US stocks

Price / sales
—
Price / book
4.8×

Cheaper than 22% of US stocks

EV / EBITDA
−8.5×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−45.3%

Higher than 23% of US stocks

Return on assets
−28.5%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Tyra Biosciences, Inc. (TYRA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tyra Biosciences, Inc. has a market value of $1.7B and an enterprise value of $1.4B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$148.6M.

  • Diluted earnings per share, trailing twelve months: $−2.40.

  • Free cash flow in the twelve months to 30 June 2026: −$109.9M.

  • Shares outstanding: 59.7M.

  • Trailing P/E: −14.2×; forward P/E: −9.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Tyra Biosciences, Inc. employs 87 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

TYRA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TYRATyra Biosciences, Inc.$1.7B
32
NVAXNovavax, Inc.$1.7B
56
ANABAnaptysBio, Inc.$1.7B
98
FTREFortrea Holdings, Inc.$1.7B
97
AVLNAvalyn Pharma, Inc.$1.7B
1
SEPNSepterna, Inc.$1.6B
90
FBRXForte Biosciences, Inc.$1.6B
—

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tyra Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TYRA news & analysis

Tyra Biosciences: 'Hold' IR-NMIBC Data September 9th 2026, With Caution Ahead For 2027 Readouts

Seeking Alpha · 6 Sept 2026neutral

Tyra Biosciences was downgraded to "Hold" ahead of the September 9th, 2026 phase 2 SURF302 data readout for dabogratinib in FGFR3-altered IR-NMIBC patients. Multiple phase 2 readouts, including SURF302, SURF303, and BEACH301, are expected to create near-term binary risk and opportunity for the company.

Why it matters — A TYRA watcher would care because the upcoming phase 2 readouts for dabogratinib present significant near-term binary risk and opportunity that could materially affect the company's outlook.

Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026

PRNewsWire · 4 Sept 2026neutral

Tyra Biosciences announced it will host a conference call and webcast on September 9, 2026, at 8:00 am ET to discuss initial clinical results from the SURF302 Phase 2 study evaluating oral dabogratinib for intermediate risk non-muscle invasive bladder cancer.

Why it matters — A TYRA watcher would care because the scheduled call will provide initial clinical data on the SURF302 study, an important development milestone for the company's dabogratinib program.

Tyra Biosciences: SURF302 Is A Worthwhile Binary Bet

Seeking Alpha · 10 Aug 2026neutral

An article discusses TYRA's dabogratinib, whose upcoming September 2026 readout could validate its FGFR3 profile and support the company's broader SNAP drug-design platform. A strong complete-response signal with a good safety profile could de-risk dabogratinib and improve TYRA's overall risk-reward profile.

Why it matters — A TYRA watcher would care because the dabogratinib readout is a key upcoming milestone that could validate the lead drug and the company's broader platform.

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights

PRNewsWire · 4 Aug 2026neutral

Tyra Biosciences reported second-quarter 2026 financial results, with cash, cash equivalents and marketable securities of $353.9 million and a runway into the second half of 2028. The company also noted that initial Phase 2 data from SURF302 are expected in September 2026, initial Phase 2 data from the BEACH301 safety sentinel cohort are now expected at the end of Q1 2027, and it appointed Jonathan Day as EVP of Clinical Development.

Why it matters — The announcement sets expected timelines for key upcoming FGFR3 (Suralta) clinical data from SURF302 and BEACH301 and confirms the company's cash runway into the second half of 2028.

FAQ

Frequently asked questions about TYRA stock

What is the TYRA stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Tyra Biosciences, Inc. have a median 12-month price target of $53, with estimates ranging from $39 to $59. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TYRA stock a buy right now?

Of the 15 analysts covering Tyra Biosciences, Inc., 14 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tyra Biosciences, Inc. 32 out of 100 across roughly 4,600 US stocks as at 7 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TYRA?

As at 7 Sept 2026, Tyra Biosciences, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (81 of 100).

Will TYRA stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +85.0% from the last close, and Ticker Nerd's factor model ranks Tyra Biosciences, Inc. 32 out of 100 as at 7 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TYRA stock forecast for 2030?

No analyst covering Tyra Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TYRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $39 to $59 over the next 12 months.

How has TYRA stock performed over the past year?

Tyra Biosciences, Inc. returned +136.0% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tyra Biosciences, Inc. do?

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target fibroblast growth factor receptor (FGFR) biology.

What is the latest news on TYRA?

The most recent item we track (Seeking Alpha, 6 Sept 2026): "Tyra Biosciences: 'Hold' IR-NMIBC Data September 9th 2026, With Caution Ahead For 2027 Readouts". Tyra Biosciences was downgraded to "Hold" ahead of the September 9th, 2026 phase 2 SURF302 data readout for dabogratinib in FGFR3-altered IR-NMIBC patients. Multiple phase 2 readouts, including SURF302, SURF303, and BEACH301, are expected to create near-term binary risk and opportunity for the company.

Company

About Tyra Biosciences, Inc.

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target fibroblast growth factor receptor (FGFR) biology. The company’s core work centers on designing small-molecule therapies for genetically defined cancers and rare skeletal disorders, using its SNÅP platform to support structure-guided drug discovery and rapid optimization. Tyra Biosciences is advancing oral dabogratinib across urologic cancers and skeletal dysplasia programs, alongside other FGFR-targeted candidates in its pipeline. Its current business is built around clinical development, translational research, and precision oncology, with an emphasis on conditions where specific genetic alterations drive disease. Headquartered in Carlsbad, California, Tyra Biosciences operates as a focused biotechnology developer serving the oncology and rare disease markets.

CEO Dr. Todd Harris Ph.D. · 87 employees · United States · https://tyra.bio